Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONCO PE trial: Optimal Duration of Rivaroxaban for Low-risk Cancer-associated Pulmonary Embolism
jRCTs051200135Completed
- Sponsor
- Bayer
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of rivaroxaban in pulmonary embolism (PE) and venous thromboembolism (VTE) (2 arms), sponsored by Bayer. Primary endpoint: VTE recurrence event at 18 months. Started Feb 2021; status: completed.
02
Drugs
rivaroxaban
03
Conditions
pulmonary embolism (PE)venous thromboembolism (VTE)
Beyond the preview
Go deeper on jRCTs051200135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051200135.